Discover 625 paid clinical trials in Arkansas. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Arkansas offers a variety of research opportunities for both healthy volunteers interested in paid clinical studies and individuals seeking trials for specific health conditions. Major research centers in Little Rock, Fayetteville, and Fort Smith are actively recruiting participants, providing access to advanced treatments and innovative medical care.
Filter
1
Filter results
Results: 625
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
for
NSCLC Stage IV
Location: Saint John, Richmond VA, Fairfax VA, Fort Lauderdale FL,
Sponsor: ImmunityBio, Inc.
Sex: All
Age: 18 - 70+
Code: NCT06745908
Phase 3, Recruiting
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
for
Castration-Resistant Prostate Carcinoma,
Location: Millville DE, Lewes DE, Rehoboth Beach DE,
Sponsor: SWOG Cancer Research Network
Sex: Male
Age: 18+
Code: NCT06470243
Phase 3, Recruiting
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
for
Metastatic Renal Cell Carcinoma,
Location: Boston MA, Bay Shore NY, Commack NY, Greenlawn NY,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT05327686
Phase 2, Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
for
Muscle Invasive Bladder Urothelial Carcinoma,
Location: Brewer ME, Gloucester MA, South Weymouth MA, Beverly MA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05987241
Phase 2, Phase 3, Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
for
Advanced Solid Tumor, PDAC, HNSCC
Location: Boston MA, New Haven CT, New York NY, St Louis MO,
Sponsor: Adcendo ApS
Sex: All
Age: 18+
Code: NCT06597721
Phase 1, Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
for
Mantle Cell Lymphoma
Location: Chicago IL, Providence RI, Westerly RI, Waterford CT,
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All
Age: 60+
Code: NCT05976763
Phase 3, Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
for
Advanced Non-Small Cell Lung Cancer,
Location: South Weymouth MA, Boston MA, Brighton MA,
Sponsor: Mirati Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT04613596
Phase 2, Phase 3, Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
for
Ganglioneuroblastoma, Nodular, Neuroblastoma
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 30
Code: NCT06172296
Phase 3, Recruiting
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
for
Endometrial Adenocarcinoma
Location: Boston MA, Providence RI, New York NY, Hackensack NJ,
Sponsor: Acrivon Therapeutics
Sex: Female
Age: 18+
Code: NCT05548296
Phase 2, Recruiting
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
for
Smoldering Plasma Cell Myeloma
Location: York Village ME, Boston MA, Westerly RI, Waterford CT,